Enliven Therapeutics, Inc. (ELVN) vs TransMedics Group, Inc. (TMDX)
A side-by-side comparison of Enliven Therapeutics, Inc. and TransMedics Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ELVN
Enliven Therapeutics, Inc.
$41.95HealthcareDelayed quote: Oct 6, 2026, 1:04 PM EDT
TMDX
TransMedics Group, Inc.
$81.33HealthcareDelayed quote: Oct 6, 2026, 1:05 PM EDT
Total return — ELVN vs TMDX
growth of $100 · dividends reinvested · last 7yELVN -24.2% (-3.9%/yr)TMDX +509.3% (+29.5%/yr)TMDX compounded faster over this window
Log scale — wide-divergence pair
ELVN TMDX
ELVN vs TMDX: by the numbers
- •ELVN is the larger company ($3.00B vs $2.81B market cap).
- •TMDX is profitable (22.69% net margin) while ELVN runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | ELVN | TMDX |
|---|---|---|
| P/E ratio | N/A | 21.07 |
| Forward P/E | N/A | 55.44 |
| P/S ratio | N/A | 4.21 |
| P/B ratio | 3.35 | 5.43 |
| EV / EBITDA | N/A | 27.16 |
| FCF yield | N/A | 2.81% |
Profitability
| Metric | ELVN | TMDX |
|---|---|---|
| Gross margin | 0.00% | 58.69% |
| Operating margin | 0.00% | 12.21% |
| Net margin | 0.00% | 22.69% |
| ROE | -11.83% | 29.28% |
| ROIC | -13.88% | 5.87% |
Growth (annualized)
| Metric | ELVN | TMDX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 86.12% |
| Total return CAGR (5Y) | 24.57% | 21.77% |
Frequently asked
- Is ELVN or TMDX more profitable?
- TMDX runs the higher net margin — ELVN at 0.00% versus TMDX at 22.69%.
- How have ELVN and TMDX total returns compared?
- Over the past 5 years, ELVN delivered 24.57% and TMDX delivered 21.77% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
TransMedics P/E ratioEnliven Therapeutics ROETransMedics ROEEnliven Therapeutics operating marginTransMedics operating marginEnliven Therapeutics revenue growthTransMedics revenue growthEnliven Therapeutics free cash flowTransMedics free cash flow
Enliven Therapeutics & TransMedics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.